share_log

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $10 Price Target

Benzinga ·  Aug 10, 2023 12:01

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment